subgroup of
trial)
→
CapableOf
→
evaluate efficacy
| Typicality: | 0.646 |
| Saliency: | 0.928 |
| in patients with ipf | 5 | other |
| specifically | 2 | manner |
| to assess pharmacokinetics | 2 | purpose |
| phase trial → evaluate → efficacy | 9 |
| phase trial → assess → efficacy | 3 |
| phase trial → be designed to assess → efficacy | 3 |
| negative | neutral | positive |
| 0.034 | 0.795 | 0.171 |
| Raw frequency | 15 |
| Normalized frequency | 0.928 |
| Modifier score | 0.500 |
| Perplexity | 258.469 |